Testing maridebart cafraglutide for weight loss in adults with type 2 diabetes and obesity
Official title: A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2)
Run by Amgen · NCT06858878 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study tests whether a new weight loss medication called maridebart cafraglutide can help adults with type 2 diabetes and obesity lose weight better than a placebo.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 999 (estimated) |
| Sponsor | Amgen Industry-sponsored |
| Locations | 83 sites (Mobile, Alabama and 82 other locations) |
| Trial ID | NCT06858878 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with a body mass index of 27 kg/m² or higher and a diagnosis of type 2 diabetes.
✕Probably not a fit
Patients with type 1 diabetes, significant recent weight changes, or certain serious health conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the efficacy and safety of maridebart cafraglutide in adults with type 2 diabetes mellitus who are overweight or obese. Participants will receive either the medication or a placebo to assess the change in body weight over the course of the study. The trial aims to demonstrate that maridebart cafraglutide is more effective than placebo in promoting weight loss among this population. The study is designed for individuals who have previously struggled with weight loss through diet and exercise.
Why it matters
Potential benefit: If successful, this treatment could provide a new option for weight management in patients with type 2 diabetes, potentially improving their overall health and diabetes control.
How similar studies have gone: Other studies have shown promising results with similar weight loss medications in patients with type 2 diabetes, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years. * Body mass index ≥ 27 kg/m\^2. * History of at least 1 self-reported unsuccessful attempt at weight loss by diet and exercise. * Diagnosis of T2DM. Exclusion Criteria: * Type 1 diabetes mellitus. * Self-reported change in body weight \> 5 kg within 90 days before screening. * Proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment. * Obesity induced by other endocrinologic disorders. * Family (first-degree relative\[s\]) or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2. * History of chronic pancreatitis or history of acute pancreatitis within 180 days before screening. * History of unstable major depressive disorder (MDD) or other severe psychiatric disorder within 2 years before screening. * Lifetime history of suicide attempt.
Where it's running
-
Alliance for Multispecialty Research Mobile
Mobile, Alabama, United States Recruiting -
Gilbert Center for Family Medicine
Gilbert, Arizona, United States Recruiting -
Desert Clinical Research
Mesa, Arizona, United States Recruiting -
Avacare Foothills Research Center
Phoenix, Arizona, United States Recruiting -
San Fernando Valley Health Institute
Canoga Park, California, United States Recruiting -
Core Healthcare Group
Cerritos, California, United States Recruiting
Show 44 more locations
-
Velocity Clinical Research Chula Vista
Chula Vista, California, United States Recruiting -
Headlands Research California
Escondido, California, United States Recruiting -
Paradigm Clinical Research
Modesto, California, United States Recruiting -
Flourish Research
Northridge, California, United States Recruiting -
University of California Irvine
Orange, California, United States Recruiting -
Empire Clinical Research
Pomona, California, United States Recruiting -
Infinity Clinical Trials
San Diego, California, United States Recruiting -
Greenwich Clinical Trials
Riverside, Connecticut, United States Recruiting -
Indago Research and Health Center
Hialeah, Florida, United States Recruiting -
San Marcus Research Clinic Inc
Miami Lakes, Florida, United States Recruiting -
Optimus U Corporation
Miami, Florida, United States Recruiting -
New Horizon Research Center
Miami, Florida, United States Recruiting -
Florida Institute for Clinical Research
Orlando, Florida, United States Recruiting -
Encore Medical Research of Weston LLC
Weston, Florida, United States Recruiting -
Conquest Research - Winter Park
Winter Park, Florida, United States Recruiting -
Alliance For Multispecialty Research - Oak Brook
Oak Brook, Illinois, United States Recruiting -
Alliance for Multispecialty Research, LLC - Park Ridge
Park Ridge, Illinois, United States Recruiting -
Endeavor Health Medical Group - Endocrinology and Diabetes- Skokie
Skokie, Illinois, United States Recruiting -
Indiana Medical Research Institute
Merrillville, Indiana, United States Recruiting -
Iowa Diabetes Research
West Des Moines, Iowa, United States Recruiting -
Alliance for Multispecialty Research Newton
Newton, Kansas, United States Recruiting -
Alliance for Multispecialty Research LLC
Wichita, Kansas, United States Recruiting -
Advanced Internal Medicine
Paducah, Kentucky, United States Recruiting -
Ima Clinical Research- Monroe
Monroe, Louisiana, United States Recruiting -
Annapolis Internal Medicine, LLC
Annapolis, Maryland, United States Recruiting -
Brigham and Womens Hospital
Boston, Massachusetts, United States Recruiting -
International Diabetes Center - HealthPartners Institute
Minneapolis, Minnesota, United States Recruiting -
Alliance for Multispecialty Research - Kansas City
Kansas City, Missouri, United States Recruiting -
Palm Research Center Inc
Las Vegas, Nevada, United States Recruiting -
Vector Clinical Trials
Sparks, Nevada, United States Recruiting -
Premier Research
Trenton, New Jersey, United States Recruiting -
Albany Medical College
Albany, New York, United States Recruiting -
Asheville Clinical Research
Asheville, North Carolina, United States Recruiting -
Physicians East
Greenville, North Carolina, United States Recruiting -
Carteret Medical Group
Morehead City, North Carolina, United States Recruiting -
West Clinical Research
Morehead City, North Carolina, United States Recruiting -
Velocity Clinical Research - Cincinnati
Blue Ash, Ohio, United States Recruiting -
Velocity Clinical Research - Springdale
Cincinnati, Ohio, United States Recruiting -
Velocity Clinical Research - Providence
East Greenwich, Rhode Island, United States Recruiting -
Medical Care LLC
Elizabethton, Tennessee, United States Recruiting -
Elligo Clinical Research Center
Austin, Texas, United States Recruiting -
Osvaldo A Brusco MD PA
Corpus Christi, Texas, United States Recruiting -
Cedar Health Research, LLC
Dallas, Texas, United States Recruiting -
Soma Clinical Trials, LLC
Denison, Texas, United States Recruiting
+33 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: Amgen Call Center
- Email: medinfo@amgen.com
- Phone: 866-572-6436
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
TQF3250 capsules for adults with type 2 diabetes and overweight/obesity
A small, early-phase study will test the safety and how the body handles different doses of TQF3250 pills in adults with type 2 diabetes who are overweight or obese.
-
Lifestyle change program to help type 2 diabetes go into remission in Pakistan
This study tests whether a structured, plant-predominant lifestyle program can put adults with type 2 diabetes in Lahore, Pakistan into remission for the first six months.
-
Colchicine for preventing cardiovascular disease in adults with type 2 diabetes
A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.
-
MWN105 injection in overweight or obese adults you may join
This early-phase trial tests whether MWN105 is safe and tolerable in overweight or obese adults in China, using a placebo comparison.
-
MWN109 tablets in adults with type 2 diabetes mellitus
A phase 2 trial tests MWN109 tablets versus placebo (and against active control semaglutide) to see if the medicine helps adults with type 2 diabetes lower their blood sugar.
-
Brain-heart axis in adults with type 2 diabetes
This study tests how brain activity and heart regulation relate to metabolic status in adults with type 2 diabetes to understand cognitive and functional health.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.